# EDGAR Filing Document

**Accession Number:** 0002071642
**File Stem:** 0001213900-25-052777
**Filing Date:** 2025-6
**Character Count:** 6930
**Document Hash:** 6d24a3d59da3e5b51c43a395856e6eab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-052777.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001213900-25-052777

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250605

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Neman-Ebrahim Yousha
- **CENTRAL INDEX KEY:** 0002071642

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42567
- **FILM NUMBER:** 251035643

**MAIL ADDRESS:**
- **STREET 1:** 23975 SORRENTO PARK
- **STREET 2:** SUITE 205
- **CITY:** CALABASAS
- **STATE:** CA
- **ZIP:** 91302
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEONC TECHNOLOGIES HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001979414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 921954864
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 23975 PARK SORRENTO
- **STREET 2:** SUITE 205
- **CITY:** CALABASAS
- **STATE:** CA
- **ZIP:** 91302
- **BUSINESS PHONE:** 310 663 7831

**MAIL ADDRESS:**
- **STREET 1:** 23975 PARK SORRENTO
- **STREET 2:** SUITE 205
- **CITY:** CALABASAS
- **STATE:** CA
- **ZIP:** 91302

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Neman-Ebrahim Yousha<br><sub>(Last) (First) (Middle)</sub><br>23975 PARK SORRENTO<br>SUITE 205<br><sub>(Street)</sub><br>CALABASAS, CA 91302<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-05 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Clinical Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock<sup>(1)</sup> | 2025-06-05 |  | A |  | 133000<sup>(2)</sup> | A | <sup>(3)</sup> | 133000 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Common Stock<sup>(4)</sup> | <sup>(3)</sup> | 2025-06-05 |  | A |  | 67000 |  | <sup>(4)</sup> | <sup>(3)</sup> | Common Stock | 67000<sup>(5)</sup> | <sup>(3)</sup> | 67000 | D |  |

---

### Footnotes:

(1) Shares of restricted common stock ("Restricted Stock") granted pursuant to Issuer's 2023 Equity Incentive Plan (the "Incentive Plan").  Pursuant to Reporting Person's Restricted Stock Award Agreement dated June 5, 2025 (the "Agreement"), Issuer granted a total of 200,000 shares of common stock to Reporting Person. Of such shares, (i) 66,000 shares vest seventh months from the date of grant, (ii) one-third, or approximately 67K shares, vest in 29 equal monthly installments thereafter, and (iii) the remaining one-third, or approximately 67K shares, are performance based with vesting predicated on achievement of certain performance metrics.

(2) See footnote 1.

(3) Not applicable.

(4) Restricted common stock granted pursuant to Issuer's Incentive Plan. Vesting and exercise of such shares are based on achievement of certain performance metrics. See also footnote 1.

(5) This is a target number only. The actual number of shares of common stock deliverable is subject to adjustment as described in the Agreement. Reporting Person may acquire shares of Issuer's common stock to the extent that the performance metrics have been achieved. See also footnote 1.

**Signature:** /s/ Yousha Neman-Ebrahim  
**Date:** 2025-06-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**